Trelegy Ellipta: Uses, Forms and Safety Reference

Trelegy Ellipta supplies three maintenance medicines in one dry-powder inhaler. Its antimuscarinic component adds practical safety considerations, and the two listed strengths do not have identical COPD and asthma labeling.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) fluticasone furoate / umeclidinium (as bromide) / vilanterol (as trifenatate)
Medicine class Inhaled corticosteroid / long-acting muscarinic antagonist / long-acting beta2 agonist (ICS/LAMA/LABA)
Forms and strengths Ellipta dry-powder inhaler: 100/62.5/25 or 200/62.5/25 mcg per actuation

What triple therapy contains

Trelegy combines fluticasone furoate, umeclidinium and vilanterol: an inhaled corticosteroid, an antimuscarinic bronchodilator and a long-acting beta2 agonist. The strengths are 100/62.5/25 or 200/62.5/25 mcg per actuation. It is distinct from two-ingredient Ellipta inhalers even when some components overlap.

Source: [1]

Adult maintenance indications and strengths

The cited US label includes COPD maintenance and asthma maintenance in adults aged 18 and older. COPD uses the 100/62.5/25 strength; adult asthma has either listed strength as a prescribing option. Trelegy is not indicated for relief of acute bronchospasm. A separate rescue plan is needed for sudden symptoms.

Source: [1]

Use the device as instructed

The label describes once-daily inhalation. Correct Ellipta opening, inhalation and dose-counter technique should be checked with the supplied device. Rinse the mouth with water and spit after use. The label contraindicates severe milk-protein allergy; a device instruction does not remove that product-specific restriction.

Source: [1]

Antimuscarinic and corticosteroid risks

Umeclidinium can worsen narrow-angle glaucoma or urinary retention. New eye pain, visual symptoms or difficulty passing urine requires prompt assessment. Other concerns include oral thrush, pneumonia in COPD and systemic corticosteroid effects. Sudden worsening after an inhalation needs immediate attention rather than an additional dose.

Source: [1]

Review duplicated bronchodilators

The label warns against additional LABA therapy and advises avoiding other anticholinergic medicines because effects can add. Strong CYP3A4 inhibitors also require review. Check the full ingredient list of every inhaler before a change, particularly when replacing Breo or another maintenance product. Triple therapy does not establish superiority for an individual.

You can explore selected factual differences in the Breo Ellipta and Trelegy Ellipta comparison, alongside each medicine’s own prescribing information.

Source: [1]

Questions and answers

Which ingredient makes Trelegy a triple product?

Umeclidinium is the antimuscarinic component alongside fluticasone furoate and vilanterol.

Are both Trelegy strengths labeled for COPD?

The cited US COPD regimen uses 100/62.5/25. The higher fluticasone strength is an adult asthma option.

Why mention urinary symptoms with an inhaler?

The antimuscarinic component can worsen urinary retention. New difficulty passing urine should be assessed promptly.

Related reading

Sources

  1. Trelegy Ellipta: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026